F-1: Galmed Pharmaceuticals Eyes $20 Million Boost Through Share Resale Program

Galmed Pharmaceuticals plans to raise up to $20 million through a share resale program with YA II PN, LTD., aiming to fund pipeline development and new ventures.

Summary

• Galmed Pharmaceuticals has filed a registration statement for the resale of up to 1,000,000 ordinary shares by YA II PN, LTD.
• These shares consist of 23,674 subsequent commitment shares and 976,326 advance shares.
• The company may receive up to $20 million in gross proceeds from sales of ordinary shares to YA under a Standby Equity Purchase Agreement.
• As of the prospectus date, Galmed has already issued 416,667 ordinary shares to YA, generating approximately $4.0 million.
• The additional shares may be purchased by YA from time to time at 97% of the lowest of the three daily VWAPs during a pricing period.
• Galmed intends to use the net proceeds for continued development of its pipeline products, new programs, business development, and general corporate purposes.
• The company's ordinary shares are listed on the Nasdaq Capital Market under the symbol GLMD.
• As of October 18, 2024, the last reported sale price of Galmed's ordinary shares on Nasdaq was $3.80 per share.
• The company effected a 1-for-12 reverse share split on August 29, 2024.
• The authorized share capital of the Company is NIS 90,000,000 divided into 50,000,000 ordinary shares, NIS 1.80 par value per share.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document outlines a potential capital raise, which can be positive if used effectively, but also carries risks of dilution. The company's plans for pipeline development are encouraging, but the reliance on a single funding source and the inherent risks of the biopharmaceutical industry temper the overall outlook.

Positives

• The potential $20 million capital injection can support the continued development of Galmed's pipeline products.
• The Standby Equity Purchase Agreement with YA provides flexible access to capital.
• The company has already secured $4.0 million from YA under the purchase agreement.
• The company plans to broaden its drug development activities based on recent Phase 3 ARMOR Study results.
• Investors from the July 2023 public offering exercised warrants to purchase 293,333 ordinary shares for $4.4 million.

Negatives

• The company will not receive any proceeds from the sale of shares by the selling shareholder.
• The purchase price of the Advance Shares that we may direct YA to purchase from time to time under the Purchase Agreement will be equal to 97% of the lowest of the three daily VWAPs during the three consecutive trading day period commencing on the date that we deliver any Advance Notice to YA, or the Pricing Period.
• The company's reliance on YA for funding could lead to substantial dilution for existing shareholders.
• The company may need to sell more ordinary shares to YA than are offered under this prospectus and the Prior Registration Statement to receive aggregate gross proceeds equal to the $20.0 million total commitment of YA under the Purchase Agreement, in which case we must first register for resale under the Securities Act additional shares, which could cause additional substantial dilution to our shareholders.

Risks

• The actual number of shares sold under the Purchase Agreement is uncertain.
• Limitations in the Purchase Agreement, including the Ownership Limitation, and our ability to meet the conditions necessary to deliver an Advance Notice, could prevent us from being able to raise funds up to the Commitment Amount.
• The resale of shares by YA could cause the market price of Galmed's ordinary shares to decline and be highly volatile.
• The company may require additional financing to sustain operations.
• The sale of a substantial amount of our ordinary shares or ordinary shares, including resale of the held by the selling shareholder in the public market could adversely affect the prevailing market price of our ordinary shares.
• The company's headquarters and operations are located in Israel, which may be adversely affected by political, economic and military instability in Israel.

Future Outlook

Galmed plans to broaden its drug development activities based on recent Phase 3 ARMOR Study results, including exploring novel Aramchol-based drug combinations for oncological treatments and cardiac fibrosis.

Industry Context

Galmed is operating in the biopharmaceutical industry, focusing on developing treatments for liver diseases and other fibro-inflammatory and oncological indications. The company is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide.

Comparison to Industry Standards

• It is difficult to compare Galmed's results to industry standards without specific financial benchmarks for similar stage biopharmaceutical companies.
• Comparable companies in the biopharmaceutical sector often include firms like Viking Therapeutics, Madrigal Pharmaceuticals, and Intercept Pharmaceuticals, which are also focused on developing treatments for liver diseases such as NASH.
• However, direct comparisons would require a detailed analysis of each company's pipeline, clinical trial results, and financial resources.

Stakeholder Impact

• Shareholders may experience dilution as a result of the issuance of new shares.
• The capital raise could enable Galmed to advance its pipeline and potentially create value for shareholders.
• Employees may benefit from the company's ability to fund its operations and development programs.
• The company's success could lead to new treatments for patients with liver diseases and other conditions.

Next Steps

• YA II PN, LTD. may sell the ordinary shares included in the prospectus in a number of different ways and at varying prices.
• Galmed plans on releasing new data from in-vitro and ex-vivo studies in these programs during the fourth quarter of 2024.

Key Dates

Keywords

Galmed Pharmaceuticals, YA II PN LTD, ordinary shares, resale, Standby Equity Purchase Agreement, GLMD, dilution, financing, Aramchol, Israel